Loading GMED charts…
May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy
Loading GMED price target model…
| Line item | Base FY2026E | Bear FY2027E | Bull FY2027E | Info |
|---|---|---|---|---|
| Revenue, $m | Revenue, $mProjected revenue for the target year. Base FY2026E is not reported yet and locks to the annual report once it’s filed. | |||
| Revenue growth | — | Revenue growthVersus the base year. Type a rate to set revenue = base × (1 + growth); editing revenue updates it. | ||
| Forward P/S | 3.41× now | Forward P/SMultiple applied at fiscal year end, when trailing revenue equals the full year. Use ▼ to pick a reference. | ||
| Diluted shares, m | 137.4 | Diluted shares, mWeighted average from the latest quarterly report. Raise it to model dilution. | ||
| Market cap, $m | 10,723 | 11,335 | 19,269 | Market cap, $mRevenue × P/S. |
| Price per share | $82.50 | $140.24 | Price per shareMarket cap ÷ diluted shares. Base column shows today’s price; type your own to override it. | |
| Weighted price targetHorizon: 14 months, to 31 Dec 2027 | $117.14Target return: +50.1% (14 months) +41.8% (annualized) | Weighted price targetBear price × bear probability + bull price × bull probability. Upside is versus the current price ($78.05); the yearly figure annualizes it over 14 months to 31 Dec 2027. | ||
| Probability | Bear 40%Bull 60% | |||
Not investment advice. This is a model whose inputs you control; it isn’t a forecast or a recommendation to buy or sell GMED. Defaults come from the company’s filings and past prices and can be wrong; check them before relying on the result.